New-Age Vaccine Adjuvants: Friend or Foe? - A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity - BioPharm

ADVERTISEMENT

New-Age Vaccine Adjuvants: Friend or Foe?
A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity


BioPharm International


112. Cooper PD, Steele EJ. Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and in vitro properties. Vaccine 1991;9:351–357.

113. Cooper PD, Steele EJ. The adjuvanticity of gamma inulin. Immunol Cell Biol 1988 66;( Pt 5–6):345–352.

114. Frazer I, Tindle R, Fernando G, Malcolm K, Herd K, McFadyn S, et al. Safety and immunogenicity of HPV16 E7/Algammulin. In T. RW, editor Vaccines for Human Papillomavirus Infection and Anogenital Disease. New York: RG Landes 1999;p. 91–104

115. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10–15.

116. Goldenthal KL, Cavagnaro JA, Alving CR, Vogel FR. Safety evaluation of vaccine adjuvants. National Cooperative Vaccine Development Working Group. AIDS Res Hum Retroviruses 1993;9:S45–S49.

117. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002;20 Suppl 3:S7–12.

118. Lindblad EB. Aluminium adjuvants—in retrospect and prospect. Vaccine 2004 22:3658–3668.

119. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001;19:4363–4372.

120. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11:S63–68.

121. Pink JR, Kieny MP. 4th meeting on novel adjuvants currently in/close to human clinical testing world health organization — organisation Mondiale de la Sante Fondation Merieux, Annecy, France, 23–25, June 2003. Vaccine 2004;22:2097–2102.

122. Seya T, Akazawa T, Tsujita T, Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med 2006;3:31–38; discussion 133–137.

123. Stills Jr., HF. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. Ilar J 2005;46:280–293.

124. Tomai MA, Johnson AG. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Response Mod 1989;8:625–643.

125. Vogel, FP, MF. A summary compendium of vaccine adjuvants and excipients. In: N.M. Powell MF, editor. Vaccine design: the subunit and adjuvant approach. New York: Plenum Publishing Corporation; 1995;p. 234–250

126. Vogel FR. Adjuvants in perspective. In: Brown, FH, editor. Modulation of the immune response to vaccine antigens. Karger; 1998.

127. Warren HSC. Future prospects for vaccine adjuvants. Crit Rev Immunol 1986;4:369–388.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here